Calandra Robert
Manag Care. 2018 Jun;27(6):19-22.
The PBM industry is under fire these days for what critics call its lack of transparency and its knotty contract language, secretive pricing schemes, and an inscrutable assortment of rebates, discounts, side deals, and administrative fees. Some see partnerships with insurers and retailers as a possible solution. Opponents see a risk of even higher drug prices.
如今，药品福利管理（PBM）行业正因批评人士所称的缺乏透明度、复杂的合同条款、隐秘的定价方案以及难以理解的回扣、折扣、私下交易和管理费而受到抨击。一些人认为与保险公司和零售商建立合作伙伴关系可能是一种解决方案。反对者则认为这存在药品价格甚至更高的风险。
